William Harless, PhD
Medical Oncology · Charleston, WVNPI 1528100948
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $299 of the $481 with a category attached, or 62.2%. It is spread thinly across 12 manufacturers, the largest accounting for just 23.5%. Reporting peaked in 2023 at $290 and has fallen 90.6% since, to $27 in 2025.
Across 16 payments — averaging $30.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$113
- Incyte Corporation$98
- Novartis$72
- Amgen$33
- Merck$33
- Alnylam Pharmaceuticals Inc.$30
- plus $101 from 6 others
What the payments were for
- Food & beverage$29962%
- Education$18238%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 2 | $113 |
| Incyte Corporation | 2 | $98 |
| Novartis | 3 | $72 |
| Amgen | 1 | $33 |
| Merck | 1 | $33 |
| Alnylam Pharmaceuticals Inc. | 1 | $30 |
| AbbVie | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Pfizer | 1 | $17 |
| Genentech USA, Inc. | 1 | $16 |
| Bristol Myers Squibb | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
How this compares
Too few medical oncology providers in West Virginiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 15 | $181,895 |
| Hydroxyurea | 17 | $411 |
| Prednisone | 28 | $142 |
| Acyclovir | 14 | $83 |
| Ondansetron Hcl | 14 | $77 |
| Potassium Chloride | 13 | $69 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 16 | $37 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Charleston
- Juan Castro-GonzalezCharleston$2K
- Justin CohenCharleston$418
- Aneel ChowdharyHuntington$420K
- Richard GoldbergMorgantown$66K
- Gerrit KimmeyHuntington$13K
- Waris WarisLogan$10K
- Rajiv KhannaBeckley$8K
- Mayez El HarakeBeckley$5K
- Joseph CaveneyMorgantown$2K
- Jennifer DotsonHuntington$398
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.